Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-03-12, Stock:LLY, The news for the past five days is as follows:
2018-03-05: NEWS1: Oral Semaglutide May Drive Solid Growth for NVO Going Forward.NEWS2: Ozempic Is Expected to Boost GLP-1 Drug Class Trajectory in 2018.NEWS3: Victoza Continues to Lead in the GLP-1 Segment in 2018.NEWS4: GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk.
2018-03-06: NEWS1: Are Alzheimer's-Focused Stocks Set for a Financial Windfall?.NEWS2: Are Alzheimer's-Focused Stocks Set for a Financial Windfall?.NEWS3: Johnson & Johnson’s Revenues in 4Q17.NEWS4: Novo Nordisk Has a Broad Portfolio for Type 2 Diabetes Care.NEWS5: Are Alzheimer&apos;s-Focused Stocks Set for a Financial Windfall?.NEWS6: Johnson & Johnson’s Valuation in February 2018.NEWS7: Diabetes Care Segment Continues to Drive Growth for NVO in 2018.NEWS8: Novo Nordisk Focuses on Raising the Bar in Research in 2018.NEWS9: How Bristol-Myers Squibb’s Opdivo Performed.NEWS10: How Did Bristol-Myers Squibb Perform in 4Q17 and Fiscal 2017?.NEWS11: Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials.
2018-03-07: NEWS1: Pharmaceutical Industry Outlook - March 2018.NEWS2: Novo Nordisk Focuses on Creating Buzz about Tresiba’s Benefits.NEWS3: Tresiba Emerged as a Blockbuster Therapy in 2017.NEWS4: Will NVO Continue to Lead the Global Insulin Market in 2018?.NEWS5: 2 Undervalued Innovators in Big Pharma.
2018-03-08: NEWS1: Celldex (CLDX) Q4 Loss Narrows, Revenues Beat, Shares Up.NEWS2: Celldex (CLDX) Q4 Loss Narrows, Revenues Beat, Shares Up.NEWS3: Analyst Recommendations for Johnson & Johnson in February 2018.NEWS4: Label Expansion May Boost Xultophy’s Sales in 2018.NEWS5: Analysts’ Estimates for Johnson & Johnson after 4Q17.NEWS6: Xultophy May Prove a Strong Growth Driver for NVO in 2018.NEWS7: What Analysts Recommend for Bristol-Myers Squibb.NEWS8: Merck to Pay $300M Upfront to Co-Develop Eisai's Cancer Drug.NEWS9: Merck to Pay $300M Upfront to Co-Develop Eisai's Cancer Drug.NEWS10: Lilly, Boehringer to Expand Jardiance Heart Failure Program.NEWS11: Lilly, Boehringer to Expand Jardiance Heart Failure Program.NEWS12: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS13: Novo Nordisk Has Developed a Portfolio of New-Generation Insulins.NEWS14: EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research.NEWS15: Lilly, Boehringer to Expand Jardiance Heart Failure Program.NEWS16: EFSD, JDRF, Lilly Extend Collaboration Supporting Type 1 Diabetes Research.NEWS17: EFSD, JDRF, Lilly Extend Collaboration Supporting Type 1 Diabetes Research.
2018-03-09: NEWS1: Top Stock Reports for Coca-Cola, Eli Lilly & Occidental Petroleum.NEWS2: What’s AstraZeneca’s Valuation in March 2018?.NEWS3: Pharma Stock Roundup: MRK Signs New Cancer Deal, DERM's Acne Candidate Fails.NEWS4: Pharma Stock Roundup: MRK Signs New Cancer Deal, DERM's Acne Candidate Fails.NEWS5: Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology.NEWS6: Pharma Stock Roundup: MRK Signs New Cancer Deal, DERM&apos;s Acne Candidate Fails.

Answer: Decrease